Alan Healthtech Secures €480M, Valued at €5.5B

French healthtech innovator Alan has successfully closed a substantial Series G funding round, raising \u20ac480 million (approximately $550 million). This significant capital injection propels the company's valuation to an impressive \u20ac5.5 billion ($6.3 billion), marking a notable increase from its previous valuation. The investment underscores the growing investor confidence in digital health solutions that prioritize proactive wellness over traditional reactive care models.

The funding round was spearheaded by global technology investment powerhouse Prosus, marking its largest commitment to the healthcare sector to date. Prosus, known for its significant stakes in companies like iFood and Swiggy, brings extensive international expansion expertise. The round also saw continued support from existing investors, including Teachers’ Venture Growth (TVG) and Index Ventures, alongside a new commitment from Dara Holdings. The completion of this transaction is contingent upon customary regulatory approvals, including clearance from the French financial authority ACPR.

Founded in 2016, Alan disrupted the French insurance market as the first new health insurer licensed in decades. It has since evolved beyond a digital insurer into a comprehensive health platform. The company champions a "prevention insurance" philosophy, integrating traditional coverage with personalized wellness plans, a 24/7 virtual clinic, an online optical service, and direct physician access, all managed through a single application. This integrated approach aims to shift the healthcare paradigm towards long-term health management and early intervention.

Alan is demonstrating robust financial performance, reporting over \u20ac800 million in Annual Recurring Revenue (ARR) for the first quarter of 2026, a 53% year-over-year increase. The company has achieved profitability in its primary market, France, and is targeting over \u20ac1 billion in ARR by the end of the year. Serving over 1.1 million members and more than 37,000 businesses across France, Spain, Belgium, and Canada, Alan employs over 850 individuals. The company's strategic focus on operational leverage, driven by its AI-centric model, has allowed for controlled headcount growth despite rapid expansion.

Artificial intelligence is central to Alan's strategy, enabling personalized prevention initiatives and streamlining healthcare navigation for its users. The partnership with Prosus is expected to accelerate this, providing Alan with access to Prosus's proprietary "Large Commerce Model" (LCM) and its global network. This collaboration is poised to bolster Alan's international reach and enhance its AI capabilities, further solidifying its position as a leader in digital health transformation.

Jean-Charles Samuelian-Werve, CEO and co-founder of Alan, highlighted the strategic choice of Prosus for their deep experience in global expansion and consumer-facing products. He also noted his advisory role with French AI leader Mistral AI, underscoring the company's commitment to cutting-edge technology. The fresh capital will fuel Alan's international expansion efforts, potential strategic acquisitions, and continued investment in AI, healthcare services, and product innovation, with the ultimate aim of establishing its prevention-focused model as the global standard for healthcare.